Using a new drug to improve heart and muscle function in patients with Duchenne muscular dystrophy
TRPC6 inhibition therapy to rescue cardiac muscle dysfunction in muscular dystrophy
This study is testing a new drug that might help protect the hearts and muscles of people with Duchenne muscular dystrophy by blocking a protein that causes damage, and it's being tried out in mice and heart tissues to see if it can really make a difference.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medical College of Wisconsin NIH-funded |
| Lab location | 1 site (Milwaukee, United States) |
| Project ID | NIH-11057688 on NIH RePORTER |
What this research studies
This research investigates a new small-molecule drug that inhibits a specific protein called TRPC6, which is known to contribute to heart and muscle problems in patients with Duchenne muscular dystrophy (DMD). The study aims to understand how this drug can reduce muscle damage and improve heart function by conducting experiments in mice and engineered heart tissues. If successful, this approach could lead to new treatments that significantly enhance the quality of life for individuals affected by DMD.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Duchenne muscular dystrophy, particularly those experiencing cardiac and skeletal muscle dysfunction.
Not a fit: Patients with other forms of muscular dystrophy or those without cardiac involvement may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel therapy that improves heart and muscle function in patients with Duchenne muscular dystrophy.
How similar studies have performed: Preliminary data from similar research have shown promising results, indicating that TRPC6 inhibition can significantly improve outcomes in models of Duchenne muscular dystrophy.
Where this research is happening
Milwaukee, United States
- Medical College of Wisconsin — Milwaukee, United States (Active)
Researchers
- Principal investigator: Lin, Brian Leei — Medical College of Wisconsin
- Study coordinator: Lin, Brian Leei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.